WO2007008093A3 - A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine - Google Patents

A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine Download PDF

Info

Publication number
WO2007008093A3
WO2007008093A3 PCT/PL2006/000047 PL2006000047W WO2007008093A3 WO 2007008093 A3 WO2007008093 A3 WO 2007008093A3 PL 2006000047 W PL2006000047 W PL 2006000047W WO 2007008093 A3 WO2007008093 A3 WO 2007008093A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
recombinant
manufacture
manufacturing
application
Prior art date
Application number
PCT/PL2006/000047
Other languages
French (fr)
Other versions
WO2007008093A2 (en
Inventor
Andrzej Fitzner
Andrzej Kesy
Boguslaw Szewczyk
Beata Gromadzka
Original Assignee
Panstwowy Inst Weterynaryjny P
Univ Gdanski
Andrzej Fitzner
Andrzej Kesy
Boguslaw Szewczyk
Beata Gromadzka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panstwowy Inst Weterynaryjny P, Univ Gdanski, Andrzej Fitzner, Andrzej Kesy, Boguslaw Szewczyk, Beata Gromadzka filed Critical Panstwowy Inst Weterynaryjny P
Priority to EP06769511A priority Critical patent/EP1904098A2/en
Publication of WO2007008093A2 publication Critical patent/WO2007008093A2/en
Publication of WO2007008093A3 publication Critical patent/WO2007008093A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The subject of the present invention is a method of manufacturing a recombinant vaccine against rabbit viral haemorrhagic disease, the vaccine and the application of a recombinant protein antigen in the manufacture of the vaccine. The subjects of the present invention facilitate the production of a recombinant capsid protein exhibiting hemagglutinin and antigenic properties, which is able to form virus-like particles (VLP) and to stimulate the production of specific antibodies in inoculated animals.
PCT/PL2006/000047 2005-07-08 2006-07-06 A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine WO2007008093A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06769511A EP1904098A2 (en) 2005-07-08 2006-07-06 A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL376122A PL205229B1 (en) 2005-07-08 2005-07-08 Method for the manufacture of recombined vaccine for the rabbit haemorrhagic disease, vaccine and application of recombined protein gene in manufacture of the vaccine
PLP-376122 2005-07-08

Publications (2)

Publication Number Publication Date
WO2007008093A2 WO2007008093A2 (en) 2007-01-18
WO2007008093A3 true WO2007008093A3 (en) 2007-04-19

Family

ID=37562591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2006/000047 WO2007008093A2 (en) 2005-07-08 2006-07-06 A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine

Country Status (3)

Country Link
EP (1) EP1904098A2 (en)
PL (1) PL205229B1 (en)
WO (1) WO2007008093A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195938A1 (en) * 2018-04-11 2019-10-17 Luminultra Technologies Ltd. Methods and kits for nucleic acid purification and other procedures
CN112480269A (en) * 2020-12-11 2021-03-12 杭州爱谨生物科技有限公司 Rabbit viral hemorrhagic disease virus VP10-VP60 recombinant protein and preparation method and application thereof
US20230192776A1 (en) * 2021-08-05 2023-06-22 VST LLC dba Medgene Labs Rabbit haemorrhagic disease virus (rhdv) vaccines
CN115444933B (en) * 2022-09-14 2023-08-29 贵州福斯特生物科技有限公司 Preparation method and application of water-soluble composite adjuvant for rabbits

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0704528A2 (en) * 1994-07-08 1996-04-03 Cyanamid Iberica, Sa Rabbit hemorrhagic disease virus (RHDV) recombinant capsids and proteins, diagnostic kits and vaccines containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0704528A2 (en) * 1994-07-08 1996-04-03 Cyanamid Iberica, Sa Rabbit hemorrhagic disease virus (RHDV) recombinant capsids and proteins, diagnostic kits and vaccines containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FITZNER A ET AL: "Application of the recombinant VP60 protein of the RHD virus for the immunization of rabbits", MEDYCYNA WETERYNARYJNA, vol. 61, no. 6, June 2005 (2005-06-01), pages 706 - 710, XP001249145, ISSN: 0025-8628 *
NAGESHA H S ET AL: "SELF-ASSEMBLY, ANTIGENICITY, AND IMMUNOGENECITY OF THE RABBIT HAEMORRHAGIC DISEASE VIRUS (CZECHOSLOVAKIAN STRAIN V-351) CAPSID PROTEIN EXPRESSED IN BACULOVIRUS", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 140, no. 6, June 1995 (1995-06-01), pages 1095 - 1108, XP009075295, ISSN: 0304-8608 *

Also Published As

Publication number Publication date
PL376122A1 (en) 2007-01-22
EP1904098A2 (en) 2008-04-02
PL205229B1 (en) 2010-03-31
WO2007008093A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
WO2004007538A3 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
WO2005068639A3 (en) Particle-induced ghrelin immune response
MX2007003171A (en) Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
WO2007019247A3 (en) Virus-like particles as vaccines for paramyxovirus
ATE447967T1 (en) PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE
WO2005020889A3 (en) Functional influenza virus-like particles (vlps)
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2014160463A8 (en) Prefusion rsv f proteins and their use
EP2601969A3 (en) Norovirus vaccine formulations
JP2009515831A5 (en)
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2007081447A8 (en) Norovirus and sapovirus antigens
WO2004009124A3 (en) Ghrelin-carrier conjugates
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
WO2007053188A3 (en) Production of multivalent virus like particles
WO2009080823A3 (en) Nerve growth factor conjugates and uses thereof
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
WO2007008093A3 (en) A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine
JP2010506926A5 (en)
WO2007066188A3 (en) Marked bovine viral diarrhea virus vaccines
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006769511

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06769511

Country of ref document: EP

Kind code of ref document: A2